MedPath

Feasibility of a Smart-Phone App for Patients With Advanced Renal Cell Carcinoma Undergoing Combination Immunotherapy

Active, not recruiting
Conditions
Renal Cell Carcinoma Stage IV
Interventions
Other: mHealth Smart Phone Application
Behavioral: eHEALS digital literacy test
Behavioral: Weekly Quiz
Behavioral: European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire
Behavioral: Patient Post Intervention Survey
Registration Number
NCT05579847
Lead Sponsor
H. Lee Moffitt Cancer Center and Research Institute
Brief Summary

The purpose of the study is to test and understand acceptability and preliminary effectiveness of a mobile educational app specifically customized to patients with advanced Renal Cell Carcinoma (RCC) receiving therapy with combination immunotherapy.

Detailed Description

Not available

Recruitment & Eligibility

Status
ACTIVE_NOT_RECRUITING
Sex
All
Target Recruitment
20
Inclusion Criteria
  • Patients with Stage IV Renal Cell Carcinoma
  • Within 3 weeks from starting combination immune checkpoint blockade with tyrosine kinase inhibitor or multikinase inhibitor
  • Estimated survival of 6 months or more
  • Able to read and speak English
Exclusion Criteria
  • Unable to read or speak English
  • Enrolled in another clinical trial

Study & Design

Study Type
OBSERVATIONAL
Study Design
Not specified
Arm && Interventions
GroupInterventionDescription
Study ParticipantsWeekly QuizParticipants with Stage IV Renal Cell Carcinoma will be recruited in the genitourinary medical oncology clinic at Moffitt Cancer Center. Upon consenting, participants will be provided with an mHealth interactive smart phone application.
Study ParticipantseHEALS digital literacy testParticipants with Stage IV Renal Cell Carcinoma will be recruited in the genitourinary medical oncology clinic at Moffitt Cancer Center. Upon consenting, participants will be provided with an mHealth interactive smart phone application.
Study ParticipantsmHealth Smart Phone ApplicationParticipants with Stage IV Renal Cell Carcinoma will be recruited in the genitourinary medical oncology clinic at Moffitt Cancer Center. Upon consenting, participants will be provided with an mHealth interactive smart phone application.
Study ParticipantsPatient Post Intervention SurveyParticipants with Stage IV Renal Cell Carcinoma will be recruited in the genitourinary medical oncology clinic at Moffitt Cancer Center. Upon consenting, participants will be provided with an mHealth interactive smart phone application.
Study ParticipantsEuropean Organization for the Research and Treatment of Cancer Quality of Life QuestionnaireParticipants with Stage IV Renal Cell Carcinoma will be recruited in the genitourinary medical oncology clinic at Moffitt Cancer Center. Upon consenting, participants will be provided with an mHealth interactive smart phone application.
Primary Outcome Measures
NameTimeMethod
Acceptability of Smart Phone Applicationat 6 months

Patient's acceptability of the smart phone application for education will be captured in the patient post education survey.

Secondary Outcome Measures
NameTimeMethod
Efficacy of Smart Phone Application -Quality of Lifeat 6 months

Efficacy of the smart phone application on patient quality of life will be assessed by the European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire (EORTC QLQ C-30) scores.

Efficacy of Smart Phone Application - Patient KnowledgeWeekly, beginning at baseline to month 6

Efficacy of the smart phone application on patient knowledge of their diagnosis and treatment will be assessed by weekly true/false quizzes.

Trial Locations

Locations (1)

Moffitt Cancer Center

🇺🇸

Tampa, Florida, United States

© Copyright 2025. All Rights Reserved by MedPath